ANTHEM BIOSCIENCES Latest Share Price (ANTHEM)
TODAY IN ONE LINE
ANTHEM rose 1.8% on light volume, outperforming Nifty's 0.0% move.
With a market cap of ₹52,034.22 Cr., it trades at a P/E of 89.17. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ANTHEM BIOSCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 127.2% YoY
- ●High Capital EfficiencyROCE of 22.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 21.1%
- ●Healthy Operating MarginsOPM is structurally strong at 43.5%
- ●High Promoter HoldingPromoters hold 71.4% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●FII AccumulationFII holding increased by 1.30% QoQ
- ●Promoter BuyingPromoters increased holdings by 71.42% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 8.2% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 72.6x
Latest ANTHEM BIOSCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
ANTHEM BIOSCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ANTHEM BIOSCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
ANTHEM BIOSCIENCES trades at a P/E of 89.17× and P/B of 16.88×, against the Healthcare sector median P/E of 45.30×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ANTHEM BIOSCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ANTHEM BIOSCIENCES — derived from the latest tape, not yesterday's close.
ANTHEM BIOSCIENCES last traded at ₹924.85 with an intraday range of ₹910–₹932.55 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹924.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 980.03 | +55.18 | +5.97% |
| R3 | 957.48 | +32.63 | +3.53% |
| R2 | 945.02 | +20.17 | +2.18% |
| R1 | 934.93 | +10.08 | +1.09% |
| PIVOT | 922.47 | -2.38 | -0.26% |
| CURRENT | 924.85 | — | — |
| S1 | 912.38 | -12.47 | -1.35% |
| S2 | 899.92 | -24.93 | -2.70% |
| S3 | 889.83 | -35.02 | -3.79% |
| S4 | 867.28 | -57.57 | -6.22% |
ANTHEM is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹910–₹923.1
Trading Inside opening range
ANTHEM BIOSCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ANTHEM BIOSCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
ANTHEM BIOSCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹52,034.22 Cr. and reported EPS of ₹10.09.
| Metric | — | Mar 2026 |
|---|---|---|
| Revenue from Operations | — | 2,124 |
| Other Income | — | 156 |
| Total Income | — | 2,280 |
| — | 812 | |
| Gross ProfitDerived | — | 1,312 |
| Gross Margin %Derived | — | 61.76% |
| — | 478 | |
| EBITDA (Operating Profit)Derived | — | 834 |
| OPM %Derived | — | 39.25% |
| — | 117 | |
| Profit Before Tax (PBT) | — | 824 |
| — | 232 | |
| Effective Tax %Derived | — | 28.20% |
| Total Profit for Period | — | 592 |
| Net Profit (Owner's PAT)Derived | — | 592 |
| Net Profit Margin %Derived | — | 27.86% |
| Earnings Per Share (EPS ₹) | — | 10.54 |
| Diluted Shares Outstanding (Cr) | — | 56 |
| Other Comprehensive Income (Net of Tax) | — | -2 |
| Total Expenses (incl. D&A & Interest) | — | 1,456 |
| Material Cost % of RevenueDerived | — | 33.59% |
| Employee Cost % of RevenueDerived | — | 13.31% |
| Other Cost % of RevenueDerived | — | 9.20% |
| Interest Coverage (x)Derived | — | 101.50x |
| Period | Mar 2026 | Trend |
|---|---|---|
| Revenue from Operations | 2,124 | |
| Other Income | 156 | |
| Total Income | 2,280 | |
812 | ||
| Gross ProfitDerived | 1,312 | |
| Gross Margin %Derived | 61.76% | |
478 | ||
| EBITDA (Operating Profit)Derived | 834 | |
| OPM %Derived | 39.25% | |
117 | ||
| Profit Before Tax (PBT) | 824 | |
232 | ||
| Effective Tax %Derived | 28.20% | |
| Total Profit for Period | 592 | |
| Net Profit (Owner's PAT)Derived | 592 | |
| Net Profit Margin %Derived | 27.86% | |
| Earnings Per Share (EPS ₹) | 10.54 | |
| Diluted Shares Outstanding (Cr) | 56 | |
| Other Comprehensive Income (Net of Tax) | -2 | |
| Total Expenses (incl. D&A & Interest) | 1,456 | |
| Material Cost % of RevenueDerived | 33.59% | |
| Employee Cost % of RevenueDerived | 13.31% | |
| Other Cost % of RevenueDerived | 9.20% | |
| Interest Coverage (x)Derived | 101.50x |
ANTHEM BIOSCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at ANTHEM BIOSCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
ANTHEM BIOSCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ANTHEM BIOSCIENCES.
Our AI distills the core fundamental drivers supporting ANTHEM BIOSCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ANTHEM BIOSCIENCES's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 116 (~2.6× the sector multiple of 45.3) would leave less room for earnings disappointment.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 16% would indicate weaker capital compounding.
ANTHEM BIOSCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ANTHEM BIOSCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ANTHEM BIOSCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ANTHEM BIOSCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ANTHEM BIOSCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ANTHEM BIOSCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ANTHEM BIOSCIENCES stood at 62.4% of traded volume, against a 20-day average of 55.8%.
ANTHEM BIOSCIENCES announcements: results, concalls, ratings, M&A.
Filings ANTHEM BIOSCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ANTHEM BIOSCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 80 documents below.
Updates
Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '.
Analysts/Institutional Investor Meet/Con. Call Updates
Anthem Biosciences Limited has informed the Exchange about Transcript
Shareholders meeting
Anthem Biosciences Limited has submitted the Exchange the voting results and a copy Srutinizers report of the 20th Annual General Meeting held on…
Analysts/Institutional Investor Meet/Con. Call Updates
Anthem Biosciences Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
ANTHEM BIOSCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ANTHEM BIOSCIENCES has declared, sequenced by announce and record date.
ANTHEM BIOSCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
ANTHEM BIOSCIENCES insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in ANTHEM BIOSCIENCES as reported to SEBI — buying and selling signals from the people who know the business best.
ANTHEM BIOSCIENCES insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
About ANTHEM BIOSCIENCES: business, sector, key facts.
What ANTHEM BIOSCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ANTHEM BIOSCIENCES operates in the Biotechnology industry under the Healthcare sector, listed as NSE: ANTHEM, BSE: 544449.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ANTHEM BIOSCIENCES (ANTHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ANTHEM BIOSCIENCES (ANTHEM)?
The current share price of ANTHEM BIOSCIENCES (ANTHEM) is ₹924.85. Today, the stock has gained by ₹16.40 (1.81%), trading in a range of ₹910.00 to ₹932.55. The stock opened at ₹914.10 with a trading volume of 1,45,668 shares.
02Is ANTHEM BIOSCIENCES stock a good investment for long-term?
ANTHEM BIOSCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹52,034.22 Cr., P/E ratio of 89.17, ROE of 21.06%, and ROCE of 22.79%. The dividend yield stands at 0.21%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ANTHEM BIOSCIENCES stock?
The 52-week high price of ANTHEM BIOSCIENCES (ANTHEM) is ₹977.55, while the 52-week low is ₹579.15. Currently trading at ₹924.85, the stock is 59.69% above its 52-week low and 5.39% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ANTHEM BIOSCIENCES stock at the current price?
Whether to buy ANTHEM BIOSCIENCES stock at ₹924.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 89.17 and P/B ratio of 16.88. Today's performance shows a gain of 1.81%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ANTHEM BIOSCIENCES and when is the next dividend?
ANTHEM BIOSCIENCES offers a dividend yield of 0.21%, which means for every ₹100 invested at the current price of ₹924.85, you can expect to receive approximately ₹0.21 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ANTHEM BIOSCIENCES?
ANTHEM BIOSCIENCES's key financial metrics include: P/E Ratio: 89.17, P/B Ratio: 16.88, ROE: 21.06%, ROCE: 22.79%, Dividend Yield: 0.21%, EPS: ₹10.09, Book Value: ₹54.17, and Debt-to-Equity: 0.01. The company's market cap stands at ₹52,034.22 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ANTHEM BIOSCIENCES stock performing today in the market?
ANTHEM BIOSCIENCES stock opened at ₹914.10 and is currently trading at ₹924.85, showing a gain of ₹16.40 (1.81%). The intraday high is ₹932.55 and low is ₹910.00. The trading volume stands at 1,45,668 shares, indicating moderate market participation today.
08What is the P/E ratio of ANTHEM BIOSCIENCES and what does it indicate?
ANTHEM BIOSCIENCES has a Price-to-Earnings (P/E) ratio of 89.17, which means investors are willing to pay 89.17 for every ₹1 of earnings. With an EPS of ₹10.09, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ANTHEM BIOSCIENCES (ANTHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.